|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1520 News |
|
| «12...345678910111213...3031» |
- FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Enrollment closed, Trial primary completion date: RELATIVES: Randomized Controlled Trial of LAIV vs TIV Vaccines in Schools (clinicaltrials.gov) - Feb 12, 2015
P=N/A, N=902, Active, not recruiting, Sponsor: Dalhousie University
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Mar 2015
- ||||| Fluarix Quadrivalent (influenza vaccine) / GSK
Enrollment closed: A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children (clinicaltrials.gov) - Feb 11, 2015
P3, N=1860, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- |||| Inavir (laninamivir) / Daiichi Sankyo
Trial completion: Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza (clinicaltrials.gov) - Feb 10, 2015
P2, N=639, Completed, Sponsor: Biota Scientific Management Pty Ltd
Recruiting --> Active, not recruiting Recruiting --> Completed
- Inavir (laninamivir) / Daiichi Sankyo
Enrollment change, Trial termination: FROSTY: Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza (clinicaltrials.gov) - Feb 5, 2015
P1/2, N=15, Terminated, Sponsor: Biota Scientific Management Pty Ltd
Recruiting --> Completed N=48 --> 15 | Recruiting --> Terminated; Study was terminated as per BARDA decision to terminate contract.
- ||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment closed, Trial primary completion date: Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults. (clinicaltrials.gov) - Feb 5, 2015
P4, N=882, Active, not recruiting, Sponsor: Pfizer
N=48 --> 15 | Recruiting --> Terminated; Study was terminated as per BARDA decision to terminate contract. Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> May 2015
- ||| GSK3206641A / GSK, GSK3206640A / GSK
Trial completion: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age (clinicaltrials.gov) - Feb 5, 2015
P1, N=424, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2015 --> May 2015 Active, not recruiting --> Completed
- || Trial primary completion date: Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old (clinicaltrials.gov) - Feb 3, 2015
P1/2, N=672, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Jun 2014
- | chlorpheniramine / Generic mfg., paracetamol / Generic mfg., dextromethorphan / Generic mfg.
Enrollment open: The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza. (clinicaltrials.gov) - Feb 2, 2015
P4, N=50, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- ||||| Flublok Quadrivalent (influenza vaccine) / Sanofi
Enrollment closed: Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age (clinicaltrials.gov) - Jan 30, 2015
P3, N=9000, Active, not recruiting, Sponsor: Protein Sciences Corporation
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||||| Flublok Quadrivalent (influenza vaccine) / Sanofi
Trial completion, Enrollment change: Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation) (clinicaltrials.gov) - Jan 30, 2015
P3, N=219, Completed, Sponsor: Protein Sciences Corporation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=300 --> 219
- | MEDI8852 / AstraZeneca
New P1 trial: Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults (clinicaltrials.gov) - Jan 30, 2015
P1, N=40, Not yet recruiting, Sponsor: MedImmune LLC
- Enrollment closed, Trial primary completion date: Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients (clinicaltrials.gov) - Jan 29, 2015
P4, N=195, Active, not recruiting, Sponsor: Butantan Institute
Active, not recruiting --> Completed | N=300 --> 219 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Aug 2014
- |||| oseltamivir / Generic mfg.
Trial primary completion date: A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants. (clinicaltrials.gov) - Jan 28, 2015
P3, N=166, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Aug 2014 Trial primary completion date: Jan 2015 --> Jun 2016
- VIS410 / Otsuka
Enrollment closed: A Study of VIS410 to Assess Safety and Pharmacokinetics (clinicaltrials.gov) - Jan 26, 2015
P1, N=41, Active, not recruiting, Sponsor: Visterra, Inc.
Trial primary completion date: Jan 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- Trial completion: H7N9 Mix and Match With AS03 and MF59 in Healthy Adults (clinicaltrials.gov) - Jan 26, 2015
P2, N=980, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: H7N9 Mix and Match With MF59 in Healthy Adults (clinicaltrials.gov) - Jan 26, 2015
P2, N=700, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Agriflu (trivalent influenza virus vaccine) / CSL Behring
New P3 trial, Preclinical: Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects (clinicaltrials.gov) - Jan 22, 2015
P3, N=1155, Completed, Sponsor: SK Chemicals Co.,Ltd.
- ||||| pimodivir (JNJ-3872) / J&J
New P2 trial, Combination therapy, Monotherapy: Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects (clinicaltrials.gov) - Jan 20, 2015
P2, N=500, Recruiting, Sponsor: Vertex Pharmaceuticals Incorporated
- ||||||| Fluarix Quadrivalent (influenza vaccine) / GSK
Trial completion: An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children (clinicaltrials.gov) - Jan 20, 2015
P3, N=12045, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Trial primary completion date: Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above (clinicaltrials.gov) - Jan 20, 2015
P1, N=196, Active, not recruiting, Sponsor: Novartis
Active, not recruiting --> Completed Trial primary completion date: May 2015 --> Nov 2015
- Enrollment open: Fever and Wheezing Events in Children After US Influenza Vaccines Using Text Messaging (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=150, Recruiting, Sponsor: Columbia University
Trial primary completion date: May 2015 --> Nov 2015 Not yet recruiting --> Recruiting
- ||||| Audenz (influenza A (H5N1) monovalent vaccine adjuvanted) / CSL Behring
Enrollment closed: Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine (clinicaltrials.gov) - Jan 15, 2015
P3, N=540, Active, not recruiting, Sponsor: Novartis
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- oseltamivir / Generic mfg.
Trial completion: Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=194, Completed, Sponsor: Marshfield Clinic Research Foundation
Recruiting --> Active, not recruiting Terminated --> Completed
- Trial primary completion date: Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects (clinicaltrials.gov) - Jan 15, 2015
P1, N=48, Recruiting, Sponsor: Autoimmune Technologies, LLC
Terminated --> Completed Trial primary completion date: Dec 2014 --> Apr 2015
- ||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Enrollment closed: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Jan 12, 2015
P3, N=688, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial primary completion date: Dec 2014 --> Apr 2015 Enrolling by invitation --> Active, not recruiting
- |||| Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults (clinicaltrials.gov) - Jan 12, 2015
P4, N=208, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion: Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected Women (clinicaltrials.gov) - Jan 12, 2015
P4, N=150, Completed, Sponsor: University of Witwatersrand, South Africa
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion: Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women (clinicaltrials.gov) - Jan 12, 2015
P3, N=800, Completed, Sponsor: University of Witwatersrand, South Africa
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion, Trial primary completion date: MatfluHIVneg: Influenza Vaccine Trial in HIV Uninfected Pregnant Women (clinicaltrials.gov) - Jan 12, 2015
P3, N=2116, Completed, Sponsor: University of Witwatersrand, South Africa
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> May 2013
- ||||| FluLaval Quadrivalent (influenza vaccine) / GSK
Enrollment closed: Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age (clinicaltrials.gov) - Jan 9, 2015
P3, N=2400, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> May 2013 Recruiting --> Active, not recruiting
- oseltamivir / Generic mfg.
Clinical: The Effect of Oseltamivir Treatment on the Yield of Polymerase Chain Reaction Test for Confirmed Influenza Infection (clinicaltrials.gov) - Jan 8, 2015
P=N/A, N=200, Not yet recruiting, Sponsor: Rambam Health Care Campus
- midodrine hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: FLUMED: Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells (clinicaltrials.gov) - Jan 8, 2015
P2, N=79, Completed, Sponsor: Hospices Civils de Lyon
Recruiting --> Active, not recruiting Recruiting --> Completed | N=161 --> 79 | Trial primary completion date: Aug 2014 --> Mar 2014
- |||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Trial primary completion date: Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers (clinicaltrials.gov) - Jan 7, 2015
P3, N=588, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed | N=161 --> 79 | Trial primary completion date: Aug 2014 --> Mar 2014 Trial primary completion date: Apr 2009 --> Jun 2008
- |||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Trial primary completion date: Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants (clinicaltrials.gov) - Jan 7, 2015
P3, N=807, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial primary completion date: Apr 2009 --> Jun 2008 Trial primary completion date: Mar 2008 --> May 2007
- |||| Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring
Trial primary completion date: Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05 (clinicaltrials.gov) - Jan 7, 2015
P3, N=1400, Active, not recruiting, Sponsor: Novartis
Trial primary completion date: Mar 2008 --> May 2007 Trial primary completion date: Jul 2016 --> Jan 2017
- |||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Trial primary completion date: Study to Compare Booster Vaccination With Pediacel (clinicaltrials.gov) - Jan 7, 2015
P3, N=847, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial primary completion date: Jul 2016 --> Jan 2017 Trial primary completion date: Mar 2008 --> Sep 2007
- |||| Fluzone Quadrivalent (influenza vaccine) / Sanofi
Trial completion: A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years (clinicaltrials.gov) - Jan 7, 2015
P4, N=402, Completed, Sponsor: bioCSL PTY LTD
Trial primary completion date: Mar 2008 --> Sep 2007 Active, not recruiting --> Completed
- |||| Trial completion: Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older (clinicaltrials.gov) - Jan 2, 2015
P2, N=367, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| IL-YANG FLU Vaccine Prefilled Syringe INJ (influenza virus vaccine quadrivalent) - IL / Yang Pharm
New P1 trial: Phase 1 Study to Assess the Safety of Inactivated Split Influenza Vaccine and Control Vaccine in Korean Volunteer (clinicaltrials.gov) - Jan 2, 2015
P1, N=100, Completed, Sponsor: Il-Yang Pharm. Co., Ltd.
- |||| Trial completion, Enrollment change, Trial primary completion date: Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients (clinicaltrials.gov) - Jan 2, 2015
P4, N=68, Completed, Sponsor: University of Alberta
Active, not recruiting --> Completed Not yet recruiting --> Completed | N=440 --> 68 | Trial primary completion date: May 2013 --> Apr 2014
- || Flucelvax (influenza virus trivalent vaccine) / CSL Behring
Trial primary completion date: Flucelvax Pregnancy Registry (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=600, Recruiting, Sponsor: Novartis
Not yet recruiting --> Completed | N=440 --> 68 | Trial primary completion date: May 2013 --> Apr 2014 Trial primary completion date: Dec 2020 --> Jun 2020
- |||| Fluarix Quadrivalent (influenza vaccine) / GSK
Trial primary completion date: An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children (clinicaltrials.gov) - Dec 25, 2014
P3, N=12045, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2020 --> Jun 2020 Trial primary completion date: Jan 2015 --> Oct 2014
- ||||||| Trial completion, Enrollment change: Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children (clinicaltrials.gov) - Dec 24, 2014
P3, N=426, Completed, Sponsor: Novartis
Trial primary completion date: Jan 2015 --> Oct 2014 Recruiting --> Completed | N=660 --> 426
- ||||| Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring
Enrollment closed: Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05 (clinicaltrials.gov) - Dec 24, 2014
P3, N=1400, Active, not recruiting, Sponsor: Novartis
Recruiting --> Completed | N=660 --> 426 Recruiting --> Active, not recruiting
- Enrollment open: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=80, Recruiting, Sponsor: Michael A. Thompson, MD, PhD
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enrollment change: Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations (clinicaltrials.gov) - Dec 19, 2014
P2, N=270, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting N=400 --> 270
- hydrocortisone / Generic mfg.
Enrollment change, Trial termination: CORTIFLU: Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu (clinicaltrials.gov) - Dec 19, 2014
P3, N=40, Terminated, Sponsor: University of Versailles
N=400 --> 270 N=448 --> 40 | Suspended --> Terminated; the H1N1 pandemic is now over, and fewer cases than expected were observed
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Enrollment open: Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old (clinicaltrials.gov) - Dec 19, 2014
P1, N=24, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=448 --> 40 | Suspended --> Terminated; the H1N1 pandemic is now over, and fewer cases than expected were observed Not yet recruiting --> Recruiting
- amantadine / Generic mfg.
Trial primary completion date: IRC003: Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications (clinicaltrials.gov) - Dec 17, 2014
P2, N=1200, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Sep 2015
- | Fluzone (influenza vaccine) / Sanofi
Trial completion: Eldery High Dose TIV 2005 (clinicaltrials.gov) - Dec 17, 2014
P2, N=414, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Sep 2014 --> Sep 2015 No longer recruiting --> Completed